Amgen, Teva to face Sensipar monopoly claims
03-12-2020
Grand Warszawski / Shutterstock.com
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar (cinacalcet) would infringe a patent earlier this week.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Sensipar, Amgen, Amneal, Zydus, Piramal